

HOSPITAL PHYSICIAN®

NEUROLOGY BOARD REVIEW MANUAL

STATEMENT OF EDITORIAL PURPOSE

The *Hospital Physician Neurology Board Review Manual* is a peer-reviewed study guide for residents and practicing physicians preparing for board examinations in neurology. Each manual reviews a topic essential to the current practice of neurology.

PUBLISHING STAFF

PRESIDENT, GROUP PUBLISHER

Bruce M. White

EDITORIAL DIRECTOR

Debra Dreger

ASSOCIATE EDITOR

Rita E. Gould

EDITORIAL ASSISTANT

Farrowh Charles

EXECUTIVE VICE PRESIDENT

Barbara T. White

EXECUTIVE DIRECTOR OF OPERATIONS

Jean M. Gaul

PRODUCTION DIRECTOR

Suzanne S. Banish

PRODUCTION ASSISTANT

Kathryn K. Johnson

ADVERTISING/PROJECT MANAGER

Patricia Payne Castle

SALES & MARKETING MANAGER

Deborah D. Chavis

NOTE FROM THE PUBLISHER:

This publication has been developed without involvement of or review by the American Board of Psychiatry and Neurology.



Endorsed by the
Association for Hospital
Medical Education

Multiple Sclerosis

Editor:

Alireza Atri, MD, PhD

Instructor in Neurology, Harvard Medical School, Assistant in Neurology, Memory Disorders Unit, Massachusetts General Hospital, Boston, MA

Associate Editor:

Tracey A. Milligan, MD

Instructor in Neurology, Harvard Medical School, Associate Neurologist, Brigham and Women's and Faulkner Hospitals, Boston, MA

Contributor:

Maria K. Houtchens, MD

Instructor in Neurology, Harvard Medical School, Associate Neurologist, Brigham and Women's Hospital, Boston, MA

Table of Contents

Introduction	2
Clinically Isolated Syndrome/Transverse Myelitis	3
Clinically Definite Multiple Sclerosis/Optic Neuritis	5
Relapsing-Remitting Multiple Sclerosis	8
Secondary Progressive Multiple Sclerosis	11
Cognitive Dysfunction in Multiple Sclerosis	12
Acute Disseminated Encephalomyelitis	13
Conclusion	14
References	14

Cover Illustration by Kathryn K. Johnson

Copyright 2006, Turner White Communications, Inc., Strafford Avenue, Suite 220, Wayne, PA 19087-3391, www.turner-white.com. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, mechanical, electronic, photocopying, recording, or otherwise, without the prior written permission of Turner White Communications. The preparation and distribution of this publication are supported by sponsorship subject to written agreements that stipulate and ensure the editorial independence of Turner White Communications. Turner White Communications retains full control over the design and production of all published materials, including selection of appropriate topics and preparation of editorial content. The authors are solely responsible for substantive content. Statements expressed reflect the views of the authors and not necessarily the opinions or policies of Turner White Communications. Turner White Communications accepts no responsibility for statements made by authors and will not be liable for any errors of omission or inaccuracies. Information contained within this publication should not be used as a substitute for clinical judgment.

Multiple Sclerosis

Maria K. Houtchens, MD

INTRODUCTION

Multiple sclerosis (MS) is a T-cell mediated autoimmune disease triggered by unknown exogenous agents (eg, viruses, bacteria) in individuals with a specific genetic background. The disease can produce various combinations of symptoms and neurologic signs that reflect the location of a lesion or lesions in different areas of the brain, spinal cord, and optic nerves. Historically, MS was considered to be a disease of the brain white matter, but recent data suggest that primary involvement of gray matter is also quite prevalent in the disease.¹

MS is the most common neurologic condition affecting young adults in their most productive years. Onset typically is in the third or fourth decade of life but in 5% of patients can be as early as 8 or as late as 70 years of age. As with most autoimmune illnesses, females are affected more often than males. Between 8000 and 10,000 new cases of MS are diagnosed each year in the United States, with an incidence ranging from 1 in 1500 people in the Southwest to 1 in 750 in the Pacific Northwest. The overall prevalence of MS in the United States is considered to be 400,000 to 500,000 patients; worldwide, MS prevalence is estimated to be close to 2.5 million people.² Prevalence varies between areas of high, medium, and low risk, with MS being more prevalent in populations located further north from the equator in the Northern Hemisphere and further south from the equator in the Southern Hemisphere. Reasons for this distribution are unknown, although there are data supporting variable geographic distribution of genetically susceptible populations and possible environmental factors.³

MS is the most common of several demyelinating disorders. The others include acute disseminated encephalomyelitis (ADEM), neuromyelitis optica (NMO, or Devic's disease), Marburg variant of MS, Schilder's disease, and Balo's concentric sclerosis. ADEM is a rapidly progressive, acute, often postinfectious or postimmunization inflammatory demyelinating condition.

ADEM often responds to high-dose steroid treatment and tends to be monophasic, with good resolution of the neurologic deficit.

NMO/Devic's disease is a recurrent or monophasic inflammatory demyelinating illness affecting the optic nerves (bilateral optic neuritis) and spinal cord (myelitis).^{4,5} Resolution of the neurologic deficit tends to be incomplete, clinical response to MS treatment (immunomodulatory medications) ineffective, and progression of disability rapid. Immunosuppressive agents and plasma exchange are sometimes effective in treatment of Devic's disease. A recently discovered serum antibody, NMO-IgG, is 70% sensitive but nearly 100% specific for Devic's disease diagnosis.⁶

Marburg variant of MS is an acute, aggressive, and rapidly progressive form of MS, which is poorly responsive to treatment. Schilder's disease is a rare, progressive demyelinating disorder that begins in childhood and is characterized by dementia, aphasia, seizures, personality changes, poor attention, tremors, balance instability, incontinence, and muscle weakness. Schilder's disease responds poorly to treatment and is generally characterized by a progressive, disabling course.⁷

Balo's concentric sclerosis is a rare variant of MS pathologically characterized by alternating rings of demyelination and spared myelin. The clinical course of Balo's concentric sclerosis was considered similar to that of Marburg variant of MS, and most reported cases have involved young adults and resulted in death within weeks to months. Recently, an increasing number of cases have been described as having prolonged survival or spontaneous remission. The most commonly reported clinical manifestations are headache, aphasia, cognitive or behavioral dysfunction, and/or seizures. Cerebrospinal fluid (CSF) studies often reveal a mononuclear inflammatory reaction and occasionally oligoclonal bands.⁸

This review presents 6 cases encompassing a range of clinical presentations of MS, MS subtypes, differential diagnosis, treatment options, and prognosis. We will also consider an algorithm for clinical decision making in cases of patients who present with MS.